EUCTR2006-006412-29-BE进行中（未招募）1 期
A Phase 1 / 2 Study of HKI-272 in combination With Paclitaxel in Subjects With Solid Tumors and Breast Cancer - study 203
Wyeth Research Division of Wyeth Pharmaceuticals Inc.0 个研究点目标入组 110 人开始时间: 2007年9月17日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 110
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Aged >=18 years.
- •2.Subjects enrolled into Part 1 must have confirmed pathologic diagnosis of a solid tumor that is not curable with available therapy for which HKI-272 plus paclitaxel is a reasonable treatment option
- •3. Subjects enrolled into Part 2 must have confirmed pathologic diagnosis of HER2 + breast cancer (current stage IV) for which paclitaxel plus HKI-272 is a reasonable treatment option.
- •4. Subjects must have received prior treatment (neoadjuvant, adjuvant, or metastatic) with a trastuzumab containing regimen (unless trastuzumab contraindicated or unavailable). (Part 2 only)
- •5. For subjects with breast cancer, HER2 gene amplified tumor (FISH) or HER2 overexpression (IHC 3 +). Documentation of HER2 status by validated test required. Otherwise tumor tissue must be available and adequate for centralized FISH testing prior to study day 1. (Part 2 only)
- •6. At least 1 measurable lesion as defined by modified RECIST criteria.
- •7. Eastern Cooperative Oncology Group (ECOG) 0 to 1 (not declining in the past two weeks)
- •8. LVEF within institutional limits of normal (by MUGA or ECHO).
- •9. Screening laboratory values within the following parameters:
- •ANC: >=1.5 × 10^9/L (1,500/mm^3)
- •Platelet count: >=75 × 10^9/L (75,000/mm^3)
- •Hemoglobin: >= 9.0 g/dL (90g/L)
- •Serum creatinine: <= 1.5 x upper limit of normal (ULN)
- •Total bilirubin: <= 1.5 × ULN
- •AST and ALT: <= 2.5 × ULN (<5 x ULN if liver metastases are present)
- •10. For women of child bearing potential, a negative urine or serum pregnancy test result before study entry. A woman of childbearing potential is one who is biologically capable of becoming pregnant. This includes women who are using contraceptives or other means of birth control or whose sexual partners are either sterile or using contraceptives.
- •11. All subjects who are not surgically sterile or postmenopausal must agree and commit to the use of a reliable method of birth control for the duration of the study and for 28 days after the last dose of test article.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. More than 1 prior cytotoxic chemotherapy treatment regimen for metastatic disease (Part 2, Arm A only) or more than 3 prior cytotoxic chemotherapy regimen for metastatic disease (Part 2, Arm B only).
- •2. Prior treatment with anthracyclines with a cumulative dose of doxorubicin of >400 mg/m2, epirubicin dose of >800 mg/m2, or the equivalent dose for other anthracyclines or derivatives.
- •3. Major surgery, chemotherapy, radical (curative intent) radiotherapy, investigational agents, or other cancer therapy within 2 weeks of treatment day 1 and recovery from all clinically significant acute adverse effects of prior therapies (excluding alopecia).
- •4. Subjects with bone or skin as the only site of disease.
- •5. Active central nervous system (CNS) metastases, as indicated by clinical symptoms, cerebral edema, and/or progressive growth (subjects with a history of CNS metastases or cord compression are allowable if they have been definitively treated and have been clinically stable for at least three months, and off steroids or anticonvulsants, before first dose of test article).
- •6. QTc interval >0.47 second or known history of QTc prolongation or Torsade de Pointes (TdP).
- •7. Known hypersensitivity to paclitaxel or Cremophor EL (polyoxyethylated castor oil).
- •8. Pregnant or breast feeding women.
- •9. Significant chronic or recent acute gastrointestinal disorder with diarrhea as a major symptom (e.g., Crohn’s disease, malabsorption, or Grade >=2 diarrhea of any etiology at baseline).
- •10. Inability or unwillingness to swallow the HKI-272.
- •11. Prior exposure to HKI-272 or any other HER2 targeted agents, except trastuzumab (Part 2 only) Prior lapatinib is permitted in Arm B of Part 2.
- •12. Treatment with a taxane within 3 months of treatment day 1.
- •13. Pre-existing grade 2 or greater motor or sensory neuropathy.
- •14. Any other cancer within 5 years prior to screening with the exception of contralateral breast carcinoma, adequately treated cervical carcinoma in situ, or adequately treated basal or squamous cell carcinoma of the skin.
- •15. Presence of clinically significant or uncontrolled cardiac disease, including congestive heart failure (New York Heart Association [NYHA] functional classification of >2), angina requiring treatment, myocardial infarction within the past 12 months, or any clinically significant supraventricular arrhythmia or ventricular arrhythmia requiring treatment or intervention.
- •16. Evidence of significant medical illness or abnormal laboratory finding that would, in the investigator’s judgment, make the subject inappropriate for this study. Examples include, but are not limited to, serious active infection (i.e. requiring intravenous antibiotic or antiviral agent), uncontrolled major seizure disorder, or significant pulmonary disorder (e.g. interstitial pneumonitis, pulmonary hypertension).
研究者
相似试验
进行中（未招募）
1 期
A Phase I/II Study of HKI-272 in Combination With Vinorelbine in Subjects With Solid Tumors and Metastatic Breast Cancer. - HKI 2204Solid tumors (part 1) and metastatic breast cancer (part 2).MedDRA version: 9.1Level: LLTClassification code 10055113Term: Breast cancer metastaticEUCTR2007-007885-39-NLWyeth Research Division of Wyeth Pharmaceuticals Inc.95
进行中（未招募）
1 期
A Phase I/II Study of HKI-272 in Combination With Vinorelbine in Subjects With Solid Tumors and Metastatic Breast Cancer.EUCTR2007-007885-39-BEWyeth Research Division of Wyeth Pharmaceuticals Inc.95
进行中（未招募）
不适用
eratinib in combination with vinorelbine in metastatic breast cancer patientsEUCTR2007-007885-39-SEPuma Biotechnology, Inc95
进行中（未招募）
1 期
A Phase I/II Study of HKI-272 in Combination With Trastuzumab (Herceptin) in Subjects With Advanced Breast Cancer.Advanced HER2 breast cancer. HER2 is a member of the epidermal growth factor (EGFR) family of receptors involved in cell proliferation, tumorigenesis, and metastasis and abnormally expressed in multiple tumor types. EGFR may also be over-expressed in breast cancer, play a role in tumorigenesis, and also confers a worse prognosis. Coexpression of EGFR family (HER1, 2 and 3) has been associated with a negative synergistic effect on 15-year disease specific survival of breast cancer patients.MedDRA version: 9.1 Level: LLT Classification code 10055113 Term: Breast cancer metastaticEUCTR2006-003215-52-FRWyeth Research Division of Wyeth Pharmaceuticals Inc.60
进行中（未招募）
1 期
A Phase I/II Study of HKI-272 in Combination With Vinorelbine in Subjects With Solid Tumors and Metastatic Breast Cancer. - HKI 2204EUCTR2007-007885-39-FRWyeth Research Division of Wyeth Pharmaceuticals Inc.95